Effective Strategies for Clinics Preparing to Implement Gene Therapy Into NMIBC Treatment Workflows

EP: 1.Evolving Guidelines: Impact of Gene Therapy and BCG Failure Redefinitions on High-Risk NMIBC Patient Management

EP: 2.Applying Evidence Standards to Guide Gene Therapy Use in BCG-Unresponsive NMIBC

EP: 3.Impact of Real-World Treatment Experience on Gene Therapy Uptake in NMIBC

EP: 4.Navigating Challenges and Impact on Workflow with New NMIBC Therapies in Practice

Now Viewing

EP: 5.Effective Strategies for Clinics Preparing to Implement Gene Therapy Into NMIBC Treatment Workflows

Video content above is prompted by the following:

Successful implementation of gene therapy in non-muscle invasive bladder cancer (NMIBC) treatment requires comprehensive institutional protocols aligned with current guidelines and clinical trial protocols. Strong partnerships with industry can facilitate initial implementation by providing training resources and leveraging experience from established programs. These collaborations help new practices avoid common implementation pitfalls and accelerate the learning curve for complex gene therapy administration procedures.

Dedicated clinic coordination significantly improves operational efficiency and patient experience. Assigning a specific clinic coordinator to maintain patient lists, manage scheduling, handle prior authorizations and serve as a single point of contact streamlines the entire treatment process. This coordination role is essential for managing the complex logistics of gene therapy administration, including proper timing of medication thawing and patient arrival coordination.

Patient comfort and medication retention strategies enhance treatment success rates. The use of rectal diazepam (10 mg gel) administered 15 minutes before installation has proven effective in reducing bladder spasms and improving tolerability across all intravesical therapies. This premedication strategy, combined with ensuring patients have appropriate transportation due to sedation, significantly reduces the risk of premature medication loss due to bladder spasms. These protocols are particularly crucial for expensive gene therapies where medication loss represents substantial financial impact.